AJP - Heart Calcium Transients and Cell-Sarcomere
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 285: H270-H276, 2003. First published March 27, 2003; doi:10.1152/ajpheart.00852.2002
0363-6135/03 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
285/1/H270    most recent
00852.2002v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hopkins, T. A.
Right arrow Articles by Lopaschuk, G. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hopkins, T. A.
Right arrow Articles by Lopaschuk, G. D.

Control of cardiac pyruvate dehydrogenase activity in peroxisome proliferator-activated receptor-{alpha} transgenic mice

Teresa A. Hopkins,1 Mary C. Sugden,2 Mark J. Holness,2 Ray Kozak,1 Jason R. B. Dyck,1 and Gary D. Lopaschuk1

1Departments of Pharmacology and Pediatrics, University of Alberta, Edmonton, Alberta, Canada T6G 2S2; and 2Division of General and Developmental Medicine, Department of Diabetes and Metabolic Medicine, St. Bartholomew's and the Royal London School of Medicine and Dentistry, Queen Mary, University of London, London, E1 4NS United Kingdom

Submitted 30 September 2002 ; accepted in final form 14 March 2003

The pyruvate dehydrogenase enzyme complex (PDC) is rate limiting for glucose oxidation in the heart. Inhibition of PDC by end-product feedback and phosphorylation by pyruvate dehydrogenase kinase (PDK) operate in concert to inhibit PDC activity. Because the transcriptional regulator peroxisome proliferator-activated receptor (PPAR)-{alpha} increases PDK expression in some tissues, we examined what role PPAR-{alpha} has in regulating glucose oxidation in hearts from mice overexpressing PPAR-{alpha} (MHC-PPAR-{alpha} mice). Glucose oxidation rates were decreased in isolated working hearts from MHC-PPAR-{alpha} mice compared with wild-type littermates (428 ± 113 vs. 771 ± 63 nmol · g dry weight-1 · min-1, respectively), which was accompanied by a parallel increase in fatty acid oxidation. However, there was no difference in PDC activity between MHC-PPAR-{alpha} and wild-type animals, even though the expression of the PDK isoform PDK1 was increased in MHC-PPAR-{alpha} mice. Glucose oxidation rates in both MHC-PPAR-{alpha} and wild-type mouse hearts were decreased after 48-h fasting (which increases PPAR-{alpha} expression) or by treatment of mice with the PPAR-{alpha} agonist WY-14,643 for 1 wk. Despite this, PDC activity in both animal groups was not altered. Taken together, these data suggest that glucose oxidation rates in the heart can be dramatically altered independent of PDK phosphorylation and inhibition of PDC by PDK. It also suggests that PPAR-{alpha} activation decreases glucose oxidation in hearts mainly by decreasing the flux of pyruvate through PDC due to negative feedback of PDC by fatty acid oxidation reaction products rather than by the phosphorylated state of the PDC complex.

glucose oxidation; fatty acid oxidation; pyruvate dehydrogenase kinase



Address for reprint requests and other correspondence: G. D. Lopaschuk, 4-23 Heritage Medical Research Center, Univ. of Alberta, Edmonton, Alberta, Canada T6G 2S2 (E-mail: gary.lopaschuk{at}ualberta.ca).




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
N. Sambandam, D. Morabito, C. Wagg, B. N. Finck, D. P. Kelly, and G. D. Lopaschuk
Chronic activation of PPAR{alpha} is detrimental to cardiac recovery after ischemia
Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H87 - H95.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
O. Dewald, S. Sharma, J. Adrogue, R. Salazar, G. D. Duerr, J. D. Crapo, M. L. Entman, and H. Taegtmeyer
Downregulation of Peroxisome Proliferator-Activated Receptor-{alpha} Gene Expression in a Mouse Model of Ischemic Cardiomyopathy Is Dependent on Reactive Oxygen Species and Prevents Lipotoxicity
Circulation, July 19, 2005; 112(3): 407 - 415.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. M. Huss and D. P. Kelly
Nuclear Receptor Signaling and Cardiac Energetics
Circ. Res., September 17, 2004; 95(6): 568 - 578.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
W. C. Stanley
Myocardial Energy Metabolism During Ischemia and the Mechanisms of Metabolic Therapies
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1_suppl): S31 - S45.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2003 by the American Physiological Society.